News about Global Pharma

Nona Biosciences, Kodiak Sciences to Power Next-Gen Antibody Therapies for Ophthalmic Diseases

The Harbour Mice platform generates fully human monoclonal antibodies in both the two heavy and two light chains (H2L2) format and the heavy chain-only (HCAb) format, eliminating the need for additional engineering or humanization.

Global Pharma | 11/12/2024 | By Aishwarya |  455

Skyhawk Gets Australian Regulatory Approval to Extend SKY-0515 Treatment Duration

HREC also agreed to the inclusion of Volumetric MRI (vMRI) measurements as an early exploratory endpoint in the trial.

Global Pharma | 11/12/2024 | By Aishwarya |  649

Steriline Strengthens its Presence in Ophthalmic Industry

Tubilux Pharma has chosen the Steriline ophthalmic line to fill glass and plastic vials with eye drops and freeze-dried products, with the aim of increasing production capacity while being fully compliant with Annex 1 and in line with industry best practices (GMP).

Global Pharma | 10/12/2024 | By Aishwarya |  519

SSI Mantra Becomes India's First CDSCO Certified Robotic System for Telesurgery

This landmark achievement positions SSI Mantra as the first surgical robotic system in India authorized to perform these advanced capabilities.

Global Pharma | 10/12/2024 | By Aishwarya |  944

Syndax Announces Positive Revuforj Data in Acute Leukemias from Multiple Trials

Revuforj is the company's oral, first-in-class menin inhibitor that is FDA approved for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients one year and older.

Global Pharma | 09/12/2024 | By Aishwarya |  543

Suven Pharma to Acquire Stake in NJ Bio with Investment of USD 64.4 Million

NJ Bio has served 150+ customers, delivered over 500 projects in 5 years, and won the prestigious World ADC Awards for four consecutive years.

Global Pharma | 09/12/2024 | By Aishwarya |  505

Torrent Pharma Signs Deal with Boehringer Ingelheim to Acquire Three Anti-Diabetes Brands

Empagliflozin is a novel sodium-glucose co-transporter-2 (SGLT-2) inhibitor that is indicated for glycemic control in adults with type 2 diabetes mellitus.

Global Pharma | 09/12/2024 | By Aishwarya |  945

Ono and Congruence to Generate Novel Small Molecule Correctors in Oncology Area

Under the terms of the agreement, Congruence will generate small molecule correctors by leveraging Congruence's proprietary drug discovery engine called, Revenir™.

Global Pharma | 07/12/2024 | By Aishwarya |  520

Alveron Pharma Secures EUR 5 Million in Seed Extension Financing

The capital provided by this new financing enables Alveron to accelerate important development activities that support OKL-1111’s readiness for further clinical studies to demonstrate safety and proof-of-concept efficacy in patients.

Global Pharma | 07/12/2024 | By Aishwarya |  302

Muna Therapeutics Partners with GSK to Develop Novel Treatments for Alzheimer's Disease

Together, Muna and GSK will assess postmortem human brain samples with spatial transcriptomics and other approaches to identify and validate potential new drug targets.

Global Pharma | 06/12/2024 | By Aishwarya |  295